US · Healthcare · Biotechnology
EPS came in at -1.16 against a street estimate of -1.15 — a miss of 0.9%.
Analysts rate Ultragenyx a buy (10 buy, 11 hold, 0 sell out of 21) with an average price target of $26.25.
CONFIDENT Q2 revenue hit $214M (record quarterly, +28.5% YoY). Three major catalysts ahead: DTX401 (GSDIa) PDUFA Aug 23, UX111 (Sanfilippo) PDUFA Sept 19, GTX-102 Phase III readout Sept/Oct. Path to 2027 profitability on track. Q2 2026 Global infrastructure enables 75% overlap between new gene therapy centers and existing Dojolvi/Mepsevii sites. 5th and 6th product launches leverage established field presence. Analysts pressed Angelman endpoint design (MDRI power, placebo risk, centralized raters, discontinuation rates), setrusumab regulatory path (BMD acceptance, additional data needed), and launch profitability sensitivity. Management emphasized FDA alignment on endpoints, consistent safety, multiple profitability levers beyond gene therapy contribution. 2026-08-04…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 10.81% |
| RTW INVESTMENTS, LLC | 7.91% |
| Vanguard Portfolio Management, LLC | 6.89% |
| AQR Capital Management LLC | 6.65% |
| State Street Corp | 6.25% |
| Vanguard Capital Management, LLC | 4.36% |
| Two Sigma Investments LLC | 3.67% |
| Sands Capital Management, LLC | 3.20% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Q3 2026 revenue was $173 million, up from $160 million in Q3 2025. For the first nine months, revenue was $523 million, up from $4 | 2026-11-04 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $173 million, up from $160 million in the third quarter of 2025. • Nine-month 2026 revenue was $5 | 2026-11-03 |
| Company announcement · Q4 2026 HEADLINE NUMBERS • On October 19, 2026, Ultragenyx Pharmaceutical Inc. and Baylor Research Institute settled patent litigation with Navinta LLC invol | 2026-10-19 |
| Material agreement · Q4 2026 HEADLINE NUMBERS • Ultragenyx Pharmaceutical agreed to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $203 million in cash. • The P | 2026-10-14 |
| Material agreement · Q4 2026 HEADLINE NUMBERS • Ultragenyx agreed to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million in cash. • The PRV was awarded | 2026-10-07 |
| Company announcement · Q3 2026 ULTRAGENYX PHARMACEUTICAL INC. - 8-K SUMMARY HEADLINE NUMBERS • FDA granted standard full approval of FAYUVI (rebisufligene etisparvovec-hopf / UX11 | 2026-09-17 |
| Company announcement · Q3 2026 ULTRAGENYX PHARMACEUTICAL INC. - 8-K SUMMARY HEADLINE NUMBERS • Report Date: September 2, 2026 • Company: Ultragenyx Pharmaceutical Inc. (Nasdaq: RA | 2026-09-02 |
| Company announcement · Q3 2026 ULTRAGENYX PHARMACEUTICAL INC. - 8-K SUMMARY HEADLINE NUMBERS • FDA granted accelerated approval for GENGLYCOS (pariglasgene brecaparvovec-opnr/DTX4 | 2026-08-19 |
Readable in the app.
| Announcement | Date |
|---|---|
| Entered into a material definitive agreement Ultragenyx Pharmaceutical filed an 8-K saying it entered into a material definitive agreement, but the provided filing excerpt does not include the agreement’s parties, financial terms, prod | 2026-10-07 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Ultragenyx — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.